ALL Video Channel
Explore the latest insights and summaries from experts in ALL.
Therapeutic Agents
Salman Fazal
Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience
- 199 views
- August 27, 2024
- 3
University of Colorado Cancer Center
Frontline Treatment of ALL: Current Standards and Emergence of CAR-T
FEATURING
Marc Schwartz
- 66 views
- August 1, 2024
Fred Hutchinson Cancer Center
Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and Beyond
FEATURING
Ryan Cassaday
- 445 views
- April 29, 2024
- 4
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies
FEATURING
David Reeves
- 239 views
- April 30, 2024
- 2
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
FEATURING
Catherine Lai
- 521 views
- March 11, 2024
- 3
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell Therapy
FEATURING
Mark Hamilton
- 194 views
- June 28, 2024
- 3
Talha Badar
Updates in ALL: Incorporating Immunotherapy in Frontline Management
- 258 views
- September 16, 2024
- 3
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 900 views
- April 16, 2024
- 5
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
FEATURING
Robert Peter Gale
- 508 views
- February 21, 2024
- 2
UChicago Medicine
Understanding CRISPR and Gene Editing in the Treatment of Heme Malignancies and Blood Disorders
FEATURING
Alan Cooper
- 244 views
- July 29, 2024
Elias Jabbour
CRS and ICANS With BiTEs in ALL - How to Manage With Dose Adjustments
- 221 views
- April 10, 2024
University of Colorado Department of Medicine
Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Going?
FEATURING
Jonathan Gutman
- 273 views
- September 19, 2024
- 1
Yale Cancer Center
Summary of Recent Advances in Adult ALL
FEATURING
Lourdes Mendez
- 137 views
- May 15, 2024
Insights from 2024 EHA Annual Meeting
Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL
FEATURING
Jose-Maria Ribera
- 106 views
- June 24, 2024
- 1
Yale Cancer Center
Summary of Promising Recent Studies in LR-MDS, HR-MDS, and R/R AML
FEATURING
Rory Shallis
- 91 views
- May 16, 2024
MyCancerHaven
Incorporating Blinatumomab and Inotuzumab Into 1L ALL Treatment
FEATURING
Ravi Vij,
Nicholas Short
- 148 views
- August 30, 2024
- 2
Yale Cancer Center
Targeting Apoptosis in Leukemia: Lessons and Challenges
FEATURING
Marina Konopleva
- 110 views
- March 15, 2024
James Essell
Bringing CAR-T for Hematologic Malignancies to the Community Practices
- 59 views
- June 20, 2024
University of Colorado Division of Hematology
Case-Based Insights on Managing Adults With R/R ALL
FEATURING
Marc Schwartz
- 57 views
- July 3, 2024
UNC Lineberger Comprehensive Cancer Center
Strategies for Managing Toxicities of Oral Oncolytics in Leukemia
- 57 views
- August 28, 2024
Rush University Medical Center
Cellular Therapy Strategies for Persistent Disease After Induction for B-ALL
FEATURING
Vinod Pullarkat
- 51 views
- May 29, 2024
MyCancerHaven
Hematopoetic Stem Cell Transplant: How I Decide
FEATURING
Ravi Vij,
Sanghee Hong
- 79 views
- August 30, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patients
FEATURING
Elias Jabbour
- 37 views
- September 6, 2024
Moffitt Cancer Center
Hot Off the Press: Experts Discuss the Latest Data in Lymphoid Diseases
- 46 views
- March 11, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients
FEATURING
Dieter Hoelzer
- 27 views
- September 6, 2024
ecancer
ASH 2023 Insights: "AUGMENT-101 - Revumenib Monotherapy in Pts With R/R KMT2Ar Acute Leukemia"
FEATURING
Ibrahim Aldoss
- 54 views
- January 18, 2024
- 1
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 146 views
- February 27, 2024
- 2
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current and Future Approaches to the Treatment of B- and T-ALL
FEATURING
Dieter Hoelzer
- 31 views
- February 16, 2024
Icahn School of Medicine at Mount Sinai
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
FEATURING
Kuo-Kai Chin
- 21 views
- July 2, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Recent Updates in ALL Treatment
FEATURING
Giovanni Martinelli
- 21 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Feasibilty of Therapy for Elderly Ph+ ALL Patients
FEATURING
Giovanni Marconi
- 24 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current Status and Future Directions for CAR T-Cell Therapy
FEATURING
Jean-Francois Rossi
- 27 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Role of ASCT in Treatment of R/R Lymphoma Patients in Resource Limited Countries
FEATURING
Adriatik Berisha
- 13 views
- February 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxicity Management
FEATURING
Ebru Erdogan
- 12 views
- August 30, 2024
ecancer
ASH 2023 Insights: "PhALLCON Study - Ponatinib vs. Imatinib in Patients With Newly Diagnosed Ph+ ALL"
FEATURING
Elias Jabbour
- 52 views
- January 19, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Inaticabtagene Autoleucel Treatment in Adult R/R B-Cell ALL in China
FEATURING
Lyu Lulu
- 7 views
- February 16, 2024